Cytokines in the pathogenesis of rheumatoid arthritis

Nature Reviews Immunology

Volumn 7, Issue 6, 2007, Pages 429-442

  McInnes, Iain B ^a   Schett, Georg ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; HLA DR4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 7; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ARGININE DEIMINASE; PROTEIN TYROSINE PHOSPHATASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICULAR CARTILAGE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 34249720998     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2094     Document Type: Review

References (129)

1. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356-361 (2003). This is an elegant overview of the pathogenesis of rheumatoid arthritis.
2. Maini, R. N. & Taylor, P. C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51, 207-229 (2000).
3. McInnes, I. B. & Liew, F. Y. Cytokine networks - towards new therapies for rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 1, 31-39 (2005).
4. van der Helm-van Mil, A. H., Wesoly, J. Z. & Huizinga, T. W. Understanding the genetic contribution to rheumatoid arthritis. Curr. Opin. Rheumatol. 17, 299-304 (2005).
5. Klareskog, L., Padyukov, L. & Alfredsson, L. Smoking as a trigger for inflammatory rheumatic diseases. Curr. Opin. Rheumatol. 19, 49-54 (2007).
6. Jimenez-Boj, E. et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J. Immunol. 175, 2579-2588 (2005).
7. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nature Clin. Pract. Rheumatol. 2, 619-626 (2006).
8. Sattar, N., McCarey, D. W., Capell, H. & McInnes, I. B. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003).
9. Panayi, G. S. Even though T-cell-directed trials have been of limited success, is there reason for optimism? Nature Clin. Pract. Rheumatol. 2, 58-59 (2006).
10. Keystone, E. C. Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr. Opin. Rheumatol. 15, 253-258 (2003).
11. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
12. McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
13. Schulze-Koops, H. & Kalden, J. R. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 15, 677-691 (2001).
14. Lubberts, E., Koenders, M. I. & van den Berg, W. B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7, 29-37 (2005).
15. Manoury-Schwartz, B. et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J. Immunol. 158, 5501-5506 (1997).
16. Vermeire, K. et al. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 158, 5507-5513 (1997).
17. H17 cells in CIA.
18. Wang, J. et al. Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J. Clin. Invest. 116, 414-421 (2006).
19. Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
20. + Th cells that cause autoimmune arthritis. J. Exp. Med. 204, 41-47 (2007).
21. Firestein, G. S. & Zvaifler, N. J. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that γ-interferon is not the primary macrophage activating factor. Arthritis Rheum. 30, 864-871 (1987).
22. Kanik, K. S. et al. Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. J. Rheumatol. 25, 16-22 (1998).
23. Ronnelid, J. et al. Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. Br. J. Rheumatol. 37, 7-14 (1998).
24. Chabaud, M. et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963-970 (1999). This paper reports the first description of IL-17 in the rheumatoid arthritis synovium.
25. Goldberg, R., Wildbaum, G., Zohar, Y., Maor, G. & Karin, N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 173, 1171-1178 (2004).
26. Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nature Immunol. 7, 929-936 (2006).
27. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nature Immunol. 7, 937-945 (2006).
28. Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852 (2007).
29. Raza, K. et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7, R784-R795 (2005). This is an important paper defining the early cytokine expression profile in synovial fluid.
30. Skapenko, A., Leipe, J., Lipsky, P. E. & Schulze-Koops, H. The role of the T cell in autoimmune inflammation. Arthritis. Res. Ther. 7 (Suppl. 2), 4-14 (2005).
31. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277-285 (2004).
32. Nadkarni, S., Mauri, C. & Ehrenstein, M. R. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med. 204, 33-39 (2007).
33. Weyand, C. M. & Goronzy, J. J. T-cell-targeted therapies in rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 2, 201-210 (2006).
34. Schroder, A. E., Greiner, A., Seyfert, C. & Berek, C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 93, 221-225 (1996).
35. Isomaki, P. et al. Prolonged exposure of T cells to TNF down-regulates TCRζ and expression of the TCR/CD3 complex at the cell surface. J. Immunol. 166, 5495-5507 (2001).
36. Veys, E. M., Menkes, C. J. & Emery, P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 40, 62-68 (1997).
37. Miossec, P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48, 594-601 (2003).
38. H2 hypothesis of T cell-mediated tissue damage. Nature Med. 13, 139-145 (2007).
39. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651 (2007).
40. Ikeuchi, H. et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52, 1037-1046 (2005).
41. Yumoto, K. et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99, 4556-4561 (2002).
42. Xu, G. et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115, 1060-1067 (2005).
43. Brennan, F. M. et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor κB pathways in tumor necrosis factor ? production in rheumatoid arthritis. Arthritis Rheum. 46, 31-41 (2002).
44. Dayer, J. M. & Burger, D. Cell-cell interactions and tissue damage in rheumatoid arthritis. Autoimmun. Rev. 3 (Suppl. 1), 14-16 (2004).
45. McInnes, I. B., Leung, B. P. & Liew, F. Y. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res. 2, 374-378 (2000).
46. Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
47. Takemura, S., Klimiuk, P. A., Braun, A., Goronzy, J. J. & Weyand, C. M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167, 4710-4718 (2001).
48. Seyler, T. M. et al. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 115, 3083-3092 (2005).
49. Ohata, J. et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J. Immunol. 174, 864-870 (2005).
50. Dorner, T. & Lipsky, P. E. Signalling pathways in B cells: implications for autoimmunity. Curr. Top. Microbiol. Immunol. 305, 213-240 (2006).
51. Takemura, S. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072-1080 (2001).
52. Manzo, A. et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347-1359 (2005).
53. Weyand, C. M. & Goronzy, J. J. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987, 140-149 (2003).
54. Braun, A., Takemura, S., Vallejo, A. N., Goronzy, J. J. & Weyand, C. M. Lymphotoxin β-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 50, 2140-2150 (2004).
55. Lindhout, E. et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells. J. Immunol. 162, 5949-5956 (1999).
56. Kang, Y. M. et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J. Exp. Med. 195, 1325-1336 (2002).
57. Brentano, F., Kyburz, D., Schorr, O., Gay, R. & Gay, S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol. 233, 90-96 (2005).
58. Seibl, R. et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162, 1221-1227 (2003).
59. Joosten, L. A. et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol. 171, 6145-6153 (2003).
60. Sacre, S. M. et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am. J. Pathol. 170, 518-525 (2007).
61. Kelso, E. B. et al. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J. Pharmacol. Exp. Ther. 316, 1017-1024 (2006).
62. Kelso, E. B. et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum. 56, 765-771 (2007).
63. Feldmann, M., Brennan, F. M. & Maini, R. N. Rheumatoid arthritis. Cell 85, 307-310 (1996). This is a seminal review of the balance of cytokine activities in rheumatoid arthritis.
64. Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440 (1996).
65. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
66. Quinn, M. A. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 27-35 (2005).
67. Ferrari-Lacraz, S. et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 173, 5818-5826 (2004).
68. Baslund, B. et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52, 2686-2692 (2005).
69. Dayer, J. M. & Bresnihan, B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum. 46, 574-578 (2002).
70. Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320 (2000).
71. Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004).
72. Choe, J. Y., Crain, B., Wu, S. R. & Corr, M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Exp. Med. 197, 537-542 (2003).
73. Gracie, J. A. et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104, 1393-1401 (1999).
74. McInnes, I. B., Liew, F. Y. & Gracie, J. A. Interleukin-18: a therapeutic target in rheumatoid arthritis? Arthritis Res. Ther. 7, 38-41 (2005).
75. Joosten, L. A. et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 103, 3298-3303 (2006).
76. Netea, M. G. et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1? and IL-6 production through a caspase 1-dependent mechanism. Proc. Natl Acad. Sci. USA 102, 16309-16314 (2005).
77. Kokkola, R. et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46, 2598-2603 (2002).
78. Morand, E. F., Leech, M. & Bernhagen, J. MIF: a new cytokine link between rheumatoid arthritis and athero sclerosis. Nature Rev. Drug Discov. 5, 399-410 (2006).
79. van der Pouw Kraan, T. C. et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 18 January 2007 (doi:10.1136/ard.2006.063412).
80. Edwards, S. W. & Hallett, M. B. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 18, 320-324 (1997).
81. Woolley, D. E. The mast cell in inflammatory arthritis. N. Engl. J. Med 348, 1709-1711 (2003).
82. Lee, D. M. et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297, 1689-1692 (2002).
83. Paniagua, R. T. et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642 (2006).
84. Dalbeth, N. & Callan, M. F. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 46, 1763-1772 (2002).
85. Bresnihan, B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 30, 17-20 (2001).
86. Schett, G. et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch. Intern. Med. 166, 2495-2501 (2006).
87. Pasco, J. A. et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 296, 1353-1355 (2006).
88. Goldring, S. R. Inflammatory mediators as essential elements in bone remodeling. Calcif. Tissue Int. 73, 97-100 (2003).
89. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
90. Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
91. Gravallese, E. M. et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250-258 (2000). This paper reports the important early description of the erosive potential in inflammatory synovitis.
92. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444 (1990).
93. Seitz, M., Loetscher, P., Fey, M. F. & Tobler, A. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br. J. Rheumatol. 33, 613-619 (1994).
94. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
95. Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
96. Shigeyama, Y. et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43, 2523-2530 (2000).
97. Horwood, N. J., Elliott, J., Martin, T. J. & Gillespie, M. T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139, 4743-4746 (1998).
98. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352 (1999).
99. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
100. Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
101. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone. Miner. Res. 19, 207-213 (2004).
102. Ritchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G. & Schwarz, E. M. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821-831 (2003).
103. Wei, S., Kitaura, H., Zhou, P., Ross, F. P. & Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115, 282-290 (2005).
104. Wong, P. K. et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158-168 (2006).
105. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
106. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
107. Udagawa, N. et al. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. 185, 1005-1012 (1997).
108. Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D. & Mundy, G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516-518 (1986).
109. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nature Med. 13, 156-163 (2007).
110. Meyer, L. H., Franssen, L. & Pap, T. The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 20, 969-981 (2006).
111. Lee, D. M. et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315, 1006-1010 (2007).
112. Pap, T., Muller-Ladner, U., Gay, R. E. & Gay, S. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2, 361-367 (2000).
113. Burger, J. A., Zvaifler, N. J., Tsukada, N., Firestein, G. S. & Kipps, T. J. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J. Clin. Invest. 107, 305-315 (2001).
114. Pap, T. Direct interaction of immunoglobulins with synovial fibroblasts: a missing link in the pathogenesis of rheumatoid arthritis? Arthritis Res. Ther. 7, 44-46 (2005).
115. Eberhardt, W., Huwiler, A., Beck, K. F., Walpen, S. & Pfeilschifter, J. Amplification of IL-1β-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-κB and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J. Immunol. 165, 5788-5797 (2000).
116. Catterall, J. B. et al. Synergistic induction of matrix metalloproteinase 1 by interleukin-1α and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum. 44, 2296-2310 (2001).
117. Van den Berg, W. B. Lessons from animal models of arthritis. Curr. Rheumatol. Rep. 4, 232-239 (2002).
118. Pettipher, E. R., Higgs, G. A. & Henderson, B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl Acad. Sci. USA 83, 8749-8753 (1986).
119. Joosten, L. A. B. et al. Interleukin-18 Promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am. J. Pathol. 165, 959-967 (2004).
120. Dudler, J., Renggli-Zulliger, N., Busso, N., Lotz, M. & So, A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann. Rheum. Dis. 59, 529-532 (2000).
121. Lubberts, E. et al. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm. Res. 51, 102-104 (2002).
122. Cai, L. et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16, 10-21 (2001).
123. Veale, D. J. & Fearon, U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract. Res. Clin. Rheumatol. 20, 941-947 (2006).
124. Paleolog, E. M. Angiogenesis in rheumatoid arthritis. Arthritis Res. 4 (Suppl. 3), 81-90 (2002).
125. Loetscher, P. et al. CCR5 is characteristic of Th1 lymphocytes. Nature 391, 344-345 (1998).
126. Haringman, J. J. & Tak, P. P. Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res. Ther. 6, 93-97 (2004).
127. Koch, A. E. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 52, 710-721 (2005).
128. Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
129. McInnes, I. B. Cytokines. In Kelley's Textbook of Rheumatology. 7th edn. (eds Harris, E. D. Jr. et al.) Ch. 15 (Elsevier Saunders, Philadelphia (2005).